Skip to main content
SpringerLink
Log in

Pathologic Hip Fractures in the Geriatric Patient

  • Chapter
  • First Online:
Geriatric Hip Fractures

  • 758 Accesses

Abstract

Pathologic hip fractures affect a unique subset of patients in the growing geriatric population. Geriatric and cancer populations require multidisciplinary care, and this intersection of patient profiles requires a unique combination of medical, orthopedic, and oncologic expertise. Treating these fractures not only requires a robust diagnostic process of laboratory, imaging, and histologic testing, but also may require complex coordination of surgical, medical, and radiation therapies. The question of whether, and how, to operate on a pathologic hip fracture often requires difficult decisions about a patient’s cancer status, expected longevity, and goals of care. Ultimately, while the goals of the treatment of pathologic fractures are the same as any other fracture – pain relief and early mobilization – the treatment of pathologic fractures can differ significantly from an otherwise identical fracture in a non-pathologic setting. With a growing geriatric population and advances in systemic therapies progressively increasing the life expectancy of those with metastatic cancer, the incidence of pathologic fractures continues to rise. All orthopedic surgeons must be familiar with the basic principles of diagnosis and appropriate treatment of these fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of metastatic bone disease. Orthop Clin North Am. 2000;31(4):515–28.

    Article  CAS  PubMed  Google Scholar 

  2. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98–101.

    CAS  PubMed  Google Scholar 

  3. Reich CD. Advances in the treatment of bone metastases. Clin J Oncol Nurs. 2003;7(6):641–6.

    Article  PubMed  Google Scholar 

  4. Stevens AR, Ewing J. Adenocarcinoma of the testis in the adult. Ann Surg. 1928;88(6):1074–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Weber KL, Randall RL, Grossman S, Parvizi J. Management of lower-extremity bone metastasis. J Bone Joint Surg. 2006;88(suppl_4):11–9.

    Article  PubMed  Google Scholar 

  6. Jacofsky DJ, Haidukewych GJ, Zhang H, Sim FH. Complications and results of arthroplasty for salvage of failed treatment of malignant pathologic fractures of the hip. Clin Orthop. 2004;427:52–6.

    Article  Google Scholar 

  7. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109(11):2334–42.

    Article  PubMed  Google Scholar 

  8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018: cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  PubMed  Google Scholar 

  9. Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126(10):2225–49.

    Article  PubMed  Google Scholar 

  10. Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18(1):44.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kumar N, Gupta B. Global incidence of primary malignant bone tumors. Curr Orthop Pract. 2016;27(5):530–4.

    Article  Google Scholar 

  12. Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop. 2013;4(4):207–17.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Renema N, Navet B, Heymann M-F, Lezot F, Heymann D. RANK-RANKL signalling in cancer. Biosci Rep 2016;36(4).

    Google Scholar 

  14. O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Breast Cancer Group, editor. Cochrane Database Syst Rev [Internet]. 2017 Oct 30 [cited 2021 Mar 16]; Available from: http://doi.wiley.com/10.1002/14651858.CD003474.pub4.

  15. Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.

    Article  CAS  PubMed  Google Scholar 

  16. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–32.

    Article  CAS  PubMed  Google Scholar 

  17. Simon MA, Bartucci EJ. The search for the primary tumor in patients with skeletal metastases of unknown origin. Cancer. 1986;58(5):1088–95.

    Article  CAS  PubMed  Google Scholar 

  18. Clayer M, Duncan W. Importance of biopsy of new bone lesions in patients with previous carcinoma. Clin Orthop. 2006;451:208–11.

    Article  PubMed  Google Scholar 

  19. Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11(6):437–41.

    Article  PubMed  Google Scholar 

  20. Kim SH, Shin K-H, Moon S-H, Jang J, Kim HS, Suh J-S, et al. Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. Cancer Med. 2017;6(6):1311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jin Y, Yuan M, Chen J, Zhang Y. Serum alkaline phosphatase predicts survival outcomes in patients with skeletal metastatic nasopharyngeal carcinoma. Clinics. 2015;70(4):264–72.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lim SM, Kim YN, Park KH, Kang B, Chon HJ, Kim C, et al. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer. 2016;16(1):385.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Lawrenz JM, Gordon J, George J, Haben C, Rubin BP, Ilaslan H, et al. Does PET/CT aid in detecting primary carcinoma in patients with skeletal metastases of unknown primary? Clin Orthop. 2020;478(11):2451–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Traina F, Errani C, Toscano A, Pungetti C, Fabbri D, Mazzotti A, et al. Current concepts in the biopsy of musculoskeletal tumors: AAOS exhibit selection. J Bone Joint Surg Am. 2015;97(2):e7.

    Article  PubMed  Google Scholar 

  25. Clark CR, Morgan C, Sonstegard DA, Matthews LS. The effect of biopsy-hole shape and size on bone strength. J Bone Joint Surg Am. 1977;59(2):213–7.

    Article  CAS  PubMed  Google Scholar 

  26. Lane JM, Sculco TP, Zolan S. Treatment of pathological fractures of the hip by endoprosthetic replacement. J Bone Joint Surg Am. 1980;62(6):954–9.

    Article  CAS  PubMed  Google Scholar 

  27. Bauer HCF, Wedin R. Survival after surgery for spinal and extremity metastases: prognostication in 241 patients. Acta Orthop Scand. 1995;66(2):143–6.

    Article  CAS  PubMed  Google Scholar 

  28. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine. 2005;30(19):2186–91.

    Article  PubMed  Google Scholar 

  29. Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, et al. The Scandinavian sarcoma group skeletal metastasis register survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand. 2004;75(sup311):11–5.

    Article  CAS  Google Scholar 

  30. Forsberg JA, Sjoberg D, Chen Q-R, Vickers A, Healey JH. Treating metastatic disease: which survival model is best suited for the clinic? Clin Orthop. 2013;471(3):843–50.

    Article  PubMed  Google Scholar 

  31. Scurrah A, Shiner CT, Stevens JA, Faux SG. Regional nerve blockade for early analgesic management of elderly patients with hip fracture - a narrative review. Anaesthesia. 2018;73(6):769–83.

    Article  CAS  PubMed  Google Scholar 

  32. Mavrogenis AF, Angelini A, Vottis C, Pala E, Calabrò T, Papagelopoulos PJ, et al. Modern palliative treatments for metastatic bone disease: awareness of advantages, disadvantages, and guidance. Clin J Pain. 2016;32(4):337–50.

    Article  PubMed  Google Scholar 

  33. Biermann JS, Holt GE, Lewis VO, Schwartz HS, Yaszemski MJ. Metastatic bone disease: diagnosis, evaluation, and treatment. J Bone Joint Surg Am. 2009;91(6):1518–30.

    PubMed  Google Scholar 

  34. Choy W-S, Kim KJ, Lee SK, Yang DS, Jeung SW, Choi HG, et al. Surgical treatment of pathological fractures occurring at the proximal femur. Yonsei Med J. 2015;56(2):460–5.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Reif TJ, Strotman PK, Kliethermes SA, Miller BJ, Nystrom LM. No consensus on implant choice for oligometastatic disease of the femoral head and neck. J Bone Oncol. 2018;12:14–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Alvi HM, Damron TA. Prophylactic stabilization for bone metastases, myeloma, or lymphoma: do we need to protect the entire bone? Clin Orthop. 2013;471(3):706–14.

    Article  PubMed  Google Scholar 

  37. Janssen SJ, Kortlever JTP, Ready JE, Raskin KA, Ferrone ML, Hornicek FJ, et al. Complications after surgical management of proximal femoral metastasis: a retrospective study of 417 patients. J Am Acad Orthop Surg. 2016;24(7):483–94.

    Article  PubMed  Google Scholar 

  38. Wedin R, Bauer HC, Rutqvist LE. Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients. Cancer. 2001;92(2):257–62.

    Article  CAS  PubMed  Google Scholar 

  39. Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K. Surgical treatment of renal cell carcinoma metastases: prognostic significance. Int Urol Nephrol. 1995;27(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  40. Fuchs B, Trousdale RT, Rock MG. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop. 2005;431:187–92.

    Article  Google Scholar 

  41. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol. 1999;35(3):197–203.

    Article  PubMed  Google Scholar 

  42. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu S-M, Tannir NM, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89(8):1794–801.

    Article  PubMed  Google Scholar 

  43. Zacherl M, Gruber G, Glehr M, Ofner-Kopeinig P, Radl R, Greitbauer M, et al. Surgery for pathological proximal femoral fractures, excluding femoral head and neck fractures: resection vs. stabilisation. Int Orthop. 2011;35(10):1537–43.

    Article  PubMed  Google Scholar 

  44. Pazionis TJC, Papanastassiou ID, Maybody M, Healey JH. Embolization of hypervascular bone metastases reduces intraoperative blood loss: a case-control study. Clin Orthop. 2014;472(10):3179–87.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Townsend PW, Smalley SR, Cozad SC, Rosenthal HG, Hassanein RE. Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. Int J Radiat Oncol Biol Phys. 1995;31(1):43–9.

    Article  CAS  PubMed  Google Scholar 

  46. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop. 1989;249:256–64.

    Article  Google Scholar 

  47. Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, et al. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. Oncologist. 2016;21(4):508–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Leng S, Chen Y, Tsai W-Y, Bhutani D, Hillyer GC, Lim E, et al. Use of bisphosphonates in elderly patients with newly diagnosed multiple myeloma. J Natl Compr Cancer Netw. 2019;17(1):22–8.

    Article  CAS  Google Scholar 

  49. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082–90.

    Article  CAS  PubMed  Google Scholar 

  50. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(Suppl 4):14–27.

    Article  CAS  PubMed  Google Scholar 

  51. Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26(4):1251–60.

    Article  CAS  PubMed  Google Scholar 

  52. Duckworth AD, McQueen MM, Tuck CE, Tobias JH, Wilkinson JM, Biant LC, et al. Effect of alendronic acid on fracture healing: a multicenter randomized placebo-controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2019;34(6):1025–32.

    Article  CAS  Google Scholar 

  53. Malawer MM, Link MP, Donaldson SS. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Wilkins Publishers; 2001.

    Google Scholar 

  54. Peterson JR, Decilveo AP, O’Connor IT, Golub I, Wittig JC. What are the functional results and complications with long stem hemiarthroplasty in patients with metastases to the proximal femur? Clin Orthop. 2017;475(3):745–56.

    Article  PubMed  Google Scholar 

  55. Cipriano CA, Arvanitis LD, Virkus WW. Use of the reamer-irrigator-aspirator may reduce tumor dissemination during intramedullary fixation of malignancies. Orthopedics. 2012;35(1):e48–52.

    Article  PubMed  Google Scholar 

  56. Henderson ER, Groundland JS, Pala E, Dennis JA, Wooten R, Cheong D, et al. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011;93(5):418–29.

    Article  PubMed  Google Scholar 

  57. Fu MC, Boddapati V, Gausden EB, Samuel AM, Russell LA, Lane JM. Surgery for a fracture of the hip within 24 hours of admission is independently associated with reduced short-term post-operative complications. Bone Joint J. 2017;99-B(9):1216–22.

    Article  CAS  PubMed  Google Scholar 

  58. Moja L, Piatti A, Pecoraro V, Ricci C, Virgili G, Salanti G, et al. Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190,000 patients. PLoS One. 2012;7(10):e46175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Shiga T, Wajima Z, Ohe Y. Is operative delay associated with increased mortality of hip fracture patients? Systematic review, meta-analysis, and meta-regression. Can J Anaesth. 2008;55(3):146–54.

    Article  PubMed  Google Scholar 

  60. Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, et al. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010;182(15):1609–16.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Varady NH, Ameen BT, Chen AF. Is delayed time to surgery associated with increased short-term complications in patients with pathologic hip fractures? Clin Orthop. 2020;478(3):607–15.

    Article  PubMed  Google Scholar 

  62. Kim JH, Seo SW, Chung CH. What factors are associated with early mortality in patients undergoing femur surgery for metastatic lung cancer? Clin Orthop. 2018;476(9):1815–22.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Chafey DH, Lewis VO, Satcher RL, Moon BS, Lin PP. Is a cephalomedullary nail durable treatment for patients with metastatic peritrochanteric disease? Clin Orthop. 2018;476(12):2392–401.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Steensma M, Boland PJ, Morris CD, Athanasian E, Healey JH. Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop. 2012;470(3):920–6.

    Article  PubMed  Google Scholar 

  65. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop. 1993;286:241–6.

    Article  Google Scholar 

  66. Guzik G. Treatment outcomes and quality of life after the implantation of modular prostheses of the proximal femur in patients with cancer metastases. Ortop Traumatol Rehabil. 2016;18(3):231–8.

    Article  PubMed  Google Scholar 

  67. Pitera T, Guzik G, Biega P. Assessment of post-operative physical performance in patients after resection arthroplasty of the proximal femur. Ortop Traumatol Rehabil. 2017;19(4):333–40.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedics and Rehabilitation, University of Florida, Gainesville, FL, USA

    Paul Rizk & Eugene Jang

  2. Department of Orthopaedic Surgery, Columbia University Medical Center, New York, NY, USA

    Wakenda Tyler

Authors
  1. Paul Rizk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugene Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wakenda Tyler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Rizk .

Editor information

Editors and Affiliations

  1. Department of Orthopaedic Surgery, Columbia University Irving Medical Center, New York, NY, USA

    Nicholas C. Danford

  2. Department of Orthopaedic Surgery, Columbia University Irving Medical Center, New York, NY, USA

    Justin K. Greisberg

  3. Department of Orthopaedic Surgery, Columbia University Irving Medical Center, New York, NY, USA

    Charles M. Jobin

  4. Department of Orthopaedic Surgery, Columbia University Irving Medical Center, New York, NY, USA

    Melvin P. Rosenwasser

  5. Department of Medicine, Division of Endocrinology, Columbia University Irving Medical Center, New York, NY, USA

    Marcella D. Walker

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rizk, P., Jang, E., Tyler, W. (2021). Pathologic Hip Fractures in the Geriatric Patient. In: Danford, N.C., Greisberg, J.K., Jobin, C.M., Rosenwasser, M.P., Walker, M.D. (eds) Geriatric Hip Fractures. Springer, Cham. https://doi.org/10.1007/978-3-030-78969-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-78969-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-78968-8

  • Online ISBN: 978-3-030-78969-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation